What vicks india does

Vicks India is a consumer healthcare brand operating in the over-the-counter (OTC) cold, cough, flu, decongestion, and baby care categories. The brand is wholly owned by Procter & Gamble and operated in India through Procter & Gamble India, with its consumer-facing presence anchored at vicks.co.in and operated from Mumbai. Its product portfolio centers on topical medicated rubs built on menthol, camphor, and eucalyptus oil formulations (the flagship Vicks VapoRub), a baby-safe non-medicated rub with aloe vera, coconut oil, lavender, and rosemary (Vicks BabyRub for infants 3 months and older), multi-symptom cold tablets combining paracetamol, diphenhydramine, phenylephrine, and caffeine (Vicks Action 500 Advanced), menthol- and honey-based cough drops and 3-in-1 lozenges, and decongestion formats including a nasal inhaler, a roll-on, and a roll-on inhaler.

The business operates a B2C consumer packaged goods model, generating revenue through unit sales of low-priced OTC SKUs distributed via India's pharmacy channel, general retail stores, and modern trade — leveraging P&G India's extensive pan-India distribution network rather than direct-to-consumer e-commerce. The brand's marketing stack is content-led: the 'Science of Healing' educational hub on the website covers baby care, cold and flu management, and illness types, complemented by active Instagram, Facebook, and Pinterest profiles. The 'Touch of Care' CSR initiative, including the #TouchOfCare Fund supporting Gauri Sawant's 'Nani Ka Ghar', functions as an emotional brand-equity vehicle. Pricing is not publicly disclosed and is set at retail through standard CPG channel mechanics. Customer segmentation is horizontal — Indian families and individuals across age groups seeking accessible, over-the-counter relief for common respiratory and baby-care needs. The brand does not operate as an independent corporate entity; it is a sub-brand/trademark within P&G India, and Vicks-specific revenue, headcount, and P&L are not separately disclosed (P&G India's overall FY26 revenue is ₹42.9 billion INR).

Name

vicks india

Legal name

Procter & Gamble

Website

https://vicks.co.in

Company type

Private

Founded year

1890

Operating status

Operating

Short description

Vicks India is a Procter & Gamble-owned consumer healthcare brand that markets over-the-counter cough, cold, flu, decongestion, and baby care remedies for Indian families and consumers across age groups.

Ownership category

akta.pro rank

Product category

OTC Consumer Healthcare

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cold, Flu & Cough Remedies (HLAIADAB)

akta.pro secondary industries

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC)

Keywords

• Cold and flu remedies
• Cough medicine
• Nasal decongestion
• OTC healthcare products
• Baby care rubs

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure

Distribution channels2 records

Marketing channels3 records

Core offering

Vicks India markets an over-the-counter consumer healthcare portfolio including menthol-based topical chest rubs (Vicks VapoRub), natural-ingredient baby rubs (Vicks BabyRub), menthol and honey cough drops and 3-in-1 lozenges, multi-symptom cold tablets (Vicks Action 500 Advanced), and portable nasal decongestants (Inhaler, Roll-On, Roll-On Inhaler). The brand targets Indian families and individuals seeking accessible, expert-tested relief from blocked nose, cough, sore throat, chest congestion, and general cold and flu symptoms.

Product overview

Vicks India is a consumer healthcare brand owned by Procter & Gamble, offering a portfolio of over-the-counter cold, cough, flu remedies, and baby care products with a legacy spanning over 100 years. The product line centers on Vicks VapoRub as the flagship product, supported by the BabyRub line for infant care, various lozenges and cough drops for sore throat relief, the Action 500 Advanced multi-symptom cold tablet, and decongestion products including inhalers and roll-ons. The portfolio addresses symptoms including blocked nose, cough, sore throat, chest congestion, and general cold and flu discomfort across baby, child, and adult segments.

Differentiator

Problem solved

Functional benefit

Brands

• Vicks VapoRub: The flagship product - a medicated vaporization ointment for cough and cold relief
• Vicks BabyRub
• Vicks Cough Drops
• Vicks Action 500 Advanced
• Vicks Inhaler
• Vicks Roll-On
• Vicks Roll-On Inhaler
• Vicks 3-in-1 Lozenges

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Dabur India: Dabur is India's largest Ayurvedic OTC and consumer healthcare company, with cough/cold remedies (Dabur Honitus), Chyawanprash, and baby care products directly competing against Vicks' VapoRub, lozenges, and BabyRub in the same chemist and general trade channels.
• Emami (Zandu): Emami owns the Zandu brand portfolio including Zandu Balm, Zandu Pancharishta, and other Ayurvedic OTC remedies that compete head-to-head with Vicks VapoRub for cough, cold, and headache relief among Indian consumers.
• Himalaya Wellness: Himalaya manufactures herbal pharmaceutical and personal care products including cough syrups, cold relief balms, and baby care (Baby Lotion, Baby Massage Oil), competing directly with Vicks' OTC cold/cough and baby-care sub-brands on 'natural ingredient' positioning.
• Patanjali Ayurved: Patanjali has rapidly scaled Ayurvedic FMCG including cough/cold remedies (Divya Madhunashini, Swasari), ayurvedic balms, and baby care products, taking shelf share from Vicks in chemist and kirana stores by leveraging the 'natural/Ayurvedic' consumer trend.
• Manforce (Mankind Pharma): Mankind Pharma is a fast-growing Indian OTC and prescription pharma company with cold/cough remedies and consumer health products that compete with Vicks in the chemist channel; an emerging direct competitor with aggressive pricing and distribution.

Broad incumbents

• Reckitt Benckiser India: Reckitt is a global OTC consumer health leader with brands like Strepsils, Dettol, and Disprin competing in the same Indian cold/cough/sore throat category as Vicks' lozenges and multi-symptom tablets; a broader FMCG incumbent with overlapping but not exclusive focus on respiratory care.
• Haleon India (formerly GSK Consumer Healthcare): Haleon operates Crocin, Otrivin, Sensodyne, and other consumer health brands in India, with nasal decongestants and OTC cold remedies directly overlapping Vicks' inhaler and Action 500 product lines; part of a broader multinational health portfolio.
• Cipla: Cipla is a leading Indian pharmaceutical company with a growing consumer healthcare and OTC business (Cofsils lozenges, Nasofix inhalers) competing in the same cough/cold/sore throat categories as Vicks, though primarily a prescription pharma company.
• Abbott India: Abbott markets consumer healthcare products in India including cough syrups and decongestants over a broader pharma portfolio, with limited but real overlap with Vicks' OTC respiratory franchise.

Regional players

• Hamdard: Hamdard operates traditional Unani/Ayurvedic healthcare products including Joshina and Safi in India, providing cultural-segment competition to Vicks among consumers preferring traditional remedies for cold and flu.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about vicks india